Bremelanotide (PT-141)

Approved human use · product-specific labels.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Its approved product, Vyleesi, treats acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Desire-related distress is the clinical target, rather than a universal increase in sexual performance. [1]

02 Potential benefits

FDA-approved for certain premenopausal women with acquired, generalized HSDD causing marked distress or interpersonal difficulty. Acts through melanocortin receptors rather than the vascular mechanism used by erectile-dysfunction medicines. It is not approved to enhance sexual performance. [1]

03 Evidence & its limits

Vyleesi is not indicated for men, postmenopausal women, or sexual-performance enhancement. It transiently raises blood pressure and is contraindicated in uncontrolled hypertension or known cardiovascular disease. Nausea and potentially persistent focal pigmentation are important trade-offs. [1]

04 Risks & unknowns

Common reactions include nausea, flushing, headache, vomiting, and injection-site reactions. Temporarily increases blood pressure and reduces heart rate; contraindicated with uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation may occur and may not resolve. [1]

05 Status & scope

Its approved product, Vyleesi, treats acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] FDA approval letter
[3] FDA VYLEESI label
[4] VYLEESI prescribing information

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.